Drug maker Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat certain eye conditions.
The company has received approval from the US Food and Drug Administration to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5%), it added.
Loteprednol Etabonate ophthalmic suspension, 0.5%, is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
ADVERTISEMENT
As per the IQVIA MAT data, the product had estimated annual sales of USD 59 million in the US.
ADVERTISEMENT
RECOMMENDED FOR YOU
Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug
Jun 30, 2025
JB Chemicals Receives USFDA Approval For Drug That Treats Depression Symptoms
Jun 24, 2025
PM Modi To Participate In Massive International Yoga Day In Andhra Pradesh On June 21
Jun 21, 2025
Cognizant To Invest Rs 1,582 Crore For New Visakhapatnam Campus, Gets Land For 99 Paise
Jun 20, 2025
POPULAR
1
After Jane Street, Uday Kotak Reminds Market's Primary Role Is Promoting Capital Formation
2
India's Rs 1 Lakh-Crore Bet On Private Sector R&D — DST Secretary Shares Ambitious Roadmap
3
New Record: Shubman Gill Becomes First Batter To Score 250 And 150 In Same Test Match
4
SEBI To Run Public Campaign On F&O Risks, Says Chairman After Jane Street Action
5